COVID Card Pilot Study to Detect Antibodies to SARS-CoV-2

Overview

This study aims to investigate the clinical performance characteristics of the novel point-of-care, semi-quantitative test for SARS-CoV-2 in the Emergency Department compared to the gold standard (ELISA).

Full Title of Study: “A Pilot Study Investigating the Clinical Performance of a Novel, Point-of-care, Semi-quantitative Test for SARS-CoV-2 Antibodies in Patients Vaccinated Against COVID-19”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 2023

Detailed Description

A prospective, non-blinded, non-randomized trial will be conducted at the Adult Emergency Department at the University of Maryland Medical Center and Adult Urgent Care Center, which is managed by the Department of Emergency Medicine, located in Baltimore, Maryland. Patients meeting eligibility criteria and who have signed the research informed consent will be enrolled in this study. Subject data collected will include demographic information and past medical history. Upon enrollment into the study, a study team member will obtain a fingerstick blood sample and a sample of blood obtained during usual care venipuncture. Both fingerstick blood and blood from venipuncture will be run on the point-of-care, semi-quantitative test. The test should be expected to result within minutes after the blood sample is added to the agglutinin. An additional tube of blood will be obtained and sent to the local central laboratory for quantitative serum SARS-CoV-2 antibody testing. Additional data will be collected on the reported or documented COVID-19 immunization status and reported or documented history of prior COVID-19 infection.

Interventions

  • Device: Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies
    • A drop of blood obtained by both finger-prick and venipuncture will be placed on the test card, which has been activated by the addition of diluent. Visual clumping of red blood cells (RBCs) will be seen within minutes if SARS-CoV-2 antibodies are present. Additionally, the COVID card is semi-quantitative, meaning that the yielded hemagglutination pattern will correlate with the concentration of antibodies in the serum. A research team member will be present at bedside to provide their interpretation based on an established visual agglutination scoring system.

Arms, Groups and Cohorts

  • COVID Card
    • Enrolled patients will receive antibody testing using both: 1) point-of-care, semi-quantitative SARS-CoV-2 antibodies test, 2) SARS-CoV-2 central laboratory antibodies test

Clinical Trial Outcome Measures

Primary Measures

  • Clinical Performance
    • Time Frame: 6 months
    • To measure the diagnostic sensitivity, specificity, and accuracy compared to the gold standard central laboratory SARS-CoV-2 antibody test.

Secondary Measures

  • Past Medical Conditions
    • Time Frame: 6 months
    • To measure the diagnostic sensitivity, specificity, and accuracy compared to the gold standard central laboratory SARS-CoV-2 antibody test relative to patient past medical conditions
  • Time Since Vaccination
    • Time Frame: 6 months
    • To measure the diagnostic sensitivity, specificity, and accuracy compared to the gold standard central laboratory SARS-CoV-2 antibody test relative to the time since vaccination
  • Inter-Rater Reliability
    • Time Frame: 6 months
    • To measure differences in interpretation (scoring) of hemagglutination patterns between study team members.
  • Type of Blood
    • Time Frame: 6 months
    • The test characteristics of blood obtained by fingerstick will be compared to that of blood obtained by venipuncture.

Participating in This Clinical Trial

Inclusion Criteria

1. Adult (age > 18 years) emergency department patients 2. ED workup includes blood testing 3. Confirmed history of vaccination against SARS-CoV-2 Exclusion Criteria:

1. Known to be pregnant at the time of evaluation 2. Incarcerated at the time of evaluation 3. Requires the use of an interpreter 4. Patient is considered immunocompromised or has any other condition that the investigator feels makes the patient unsuitable for study inclusion. 5. Has any other condition that the investigator feels makes the patient unsuitable for study inclusion

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Maryland, Baltimore
  • Provider of Information About this Clinical Study
    • Principal Investigator: Richard Gentry Wilkerson, Associate Professor – University of Maryland, Baltimore
  • Overall Official(s)
    • Richard G Wilkerson, MD, Principal Investigator, University of Maryland School of Medicine
  • Overall Contact(s)
    • Richard G Wilkerson, MD, (410) 328-4237, gwilkerson@som.umaryland.edu

References

Kruse RL, Huang Y, Lee A, Zhu X, Shrestha R, Laeyendecker O, Littlefield K, Pekosz A, Bloch EM, Tobian AAR, Wang ZZ. A Hemagglutination-Based Semiquantitative Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels. J Clin Microbiol. 2021 Nov 18;59(12):e0118621. doi: 10.1128/JCM.01186-21. Epub 2021 Sep 1.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.